Insider Brief
- ArteraAI has secured an additional $20 million in funding from notable investors, including Prosperity7 Ventures and EDBI, to advance its AI-based predictive and prognostic cancer tests and support international expansion and commercial growth.
- The funding will further ArteraAI’s mission to personalize cancer therapy through its AI-enabled tests, following a recent CMS decision on the payment rate for the ArteraAI Prostate Test, aimed at enhancing accessibility to personalized care.
- ArteraAI, emerging from stealth mode with $90M initial funding, has made significant progress including securing a Medicare payment rate and laying the groundwork for global expansion, with its AI-driven tests offering personalized cancer care regimens.
PRESS RELEASE — SAN FRANCISCO /February 1, 2024— (BUSINESS WIRE) — ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, announced today that it has secured an additional $20 million in capital fueled by several prominent large investment funds including Prosperity7 Ventures, Singapore-based global investor EDBI, Walden Catalyst Ventures, Wilson Sonsini Goodrich & Rosati, and Trium Ventures, along with investors Navin Chaddha, Rajiv Khemani (AISpace VC), and Andrew & Elliott Tan (A&E Investment LLC).
“The infusion of this additional funding is a crucial catalyst, propelling ArteraAI forward in its mission to personalize cancer therapy through AI-enabled predictive and prognostic tests,” said Andre Esteva, CEO and Co-Founder of ArteraAI. “We are committed to ushering in the era of precision medicine, and stewarding this investment strategically to aid in our international expansion and commercial growth.”
This funding announcement follows closely on the heels of ArteraAI’s recent achievement of the Centers for Medicare and Medicaid Services (CMS) decision on the payment rate for the ArteraAI Prostate Test. The decision helps to ensure broader accessibility to AI-enabled personalized care, benefiting a larger population.
“Investing in ArteraAI wasn’t just a financial decision, but a testament to ArteraAI which is globally revolutionizing patient care,” said Abhishek Shukla at Prosperity7 Ventures. “We are thrilled to be part of the journey as ArteraAI continues its mission to provide patients with access to personalized cancer treatment plans.”
Less than a year ago, ArteraAI emerged from stealth mode with an initial funding of $90M. Since then, the company has made significant strides, obtaining a Medicare payment rate, growing distribution and establishing a solid foundation for international expansion through strategic global partnerships to continue its research.
“ArteraAI’s AI-driven tests represent a transformative approach to designing tailored cancer care regimens. This offers a glimpse into the future where cancer care is truly personalized, aligning with Singapore’s efforts to digitize healthcare and harness AI to enable precision medicine,” said Dr. Jolene Ooi, Senior Principal at EDBI. “We are excited to be part of their growth story and look forward to supporting its foray into Asia.”
To learn more about ArteraAI visit Artera.ai.
About ArteraAI
ArteraAI is a leading precision medicine company developing AI tests to personalize cancer therapy. ArteraAI offers an AI-enabled test that is the first of its kind to provide both predictive and prognostic results for patients with localized prostate cancer: ArteraAI Prostate Test.
ArteraAI’s multimodal artificial intelligence (MMAI) biomarker test leverages a unique algorithm that assesses digital images from a patient’s biopsy and learns from a patient’s clinical data. The AI combines this information to predict whether a patient will benefit from a particular therapy and determine their prognosis and has been validated using many Phase 3 randomized trials.
ArteraAI Prostate Test is the first test that can both predict therapy benefit and prognosticate long-term outcomes in localized prostate cancer. The test is clinically available through our CLIA-certified laboratory in Jacksonville, Florida and can be ordered online at Artera.ai.
About Prosperity7 Ventures
Prosperity7 Ventures is the diversified growth fund of Aramco Ventures, a subsidiary of Aramco, the world’s leading integrated energy and chemicals company. The fund’s name derives from “Prosperity Well,” the seventh oil well drilled in Saudi Arabia and the first to strike commercial oil, paving the way to prosperity. Bringing forward this pioneering history, Prosperity7 invests globally with a long-term view in breakthrough technologies and transformational business models that bring prosperity and positive impacts on a vast scale. Official website: https://www.prosperity7vc.com/
About EDBI
Investing since 1991, EDBI is a Singapore-based global investor in select high-growth technologies spanning sectors across Information & Communication Technology, Emerging Technology and Healthcare. As a value-creating investor, we support companies aiming to expand in Asia and globally through Singapore with our extensive network, resources and expertise. For more information, visit www.edbi.com
Contacts
Media:
Lesley Swiger
Antenna
lesley.swiger@antennagroup.com
(570) 856–4438
